about
Characterization of binding mode of action of a blocking anti-platelet-derived growth factor (PDGF)-B monoclonal antibody, MOR8457, reveals conformational flexibility and avidity needed for PDGF-BB to bind PDGF receptor-βProbing the ligand-induced conformational change in HLA-DR1 by selective chemical modification and mass spectrometric mapping.Blocking extracellular activation of myostatin as a strategy for treating muscle wasting.PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancerSelective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscapeBiophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Non-Human Primates of the Anti-PD-1 Antibody PembrolizumabA Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin ActivationModeling and mitigation of high-concentration antibody viscosity through structure-based computer-aided protein design
P50
Q27698052-204DF7D2-6CE8-4152-9BDB-E2679C72B9F2Q33225288-2888175C-E294-4AF6-9435-29831FB3732FQ48514411-452BECC3-6AF9-422E-946B-CE062E3D4B06Q56898302-5BF89877-328F-4C99-93C0-E819E41A5ECDQ90660907-9F992C9F-581D-42EC-8169-8F878FEC9597Q90766325-920E6E99-1960-4480-9B24-5A9FCA56C078Q92196620-C2E1EB98-D1A5-4935-A8FA-A3A8EE4674F2Q94606169-7B7F9CE3-9B87-4A3E-81F9-D4D4CE354791
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Gregory J Carven
@en
Gregory J Carven
@nl
type
label
Gregory J Carven
@en
Gregory J Carven
@nl
prefLabel
Gregory J Carven
@en
Gregory J Carven
@nl
P31
P496
0000-0002-8468-6323